Current methods for detecting and assessing HIV-1 antibody resistance
Antiretroviral therapy is the standard treatment for HIV, but it requires daily use and can cause side effects. Despite being available for decades, there are still 1.5 million new infections and 700,000 deaths each year, highlighting the need for better therapies. Broadly neutralizing antibodies (b...
Saved in:
| Main Authors: | Stanley Odidika, Martin Pirkl, Thomas Lengauer, Philipp Schommers |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1443377/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
by: Yubin Liu, et al.
Published: (2020-01-01) -
Defining criteria for broadly neutralizing HIV antibodies
by: Elizabeth-Sharon David-Fung, et al.
Published: (2025-07-01) -
Multiple Mechanisms of HIV-1 Resistance to PGT135 in a Chinese Subtype B’ Slow Progressor
by: Yuanyuan Hu, et al.
Published: (2025-06-01) -
Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad‐Neutralizing Antibody Response against SARS‐CoV‐2 Omicron Subvariants
by: Guangxu Zhang, et al.
Published: (2025-07-01) -
Ab initio prediction of specific phospholipid complexes and membrane association of HIV-1 MPER antibodies by multi-scale simulations
by: Colleen A Maillie, et al.
Published: (2025-04-01)